BURU vs IPGP vs LYRA vs LASE vs NPKI

For growth investors, NPK International Inc.

(NPKI) is the stronger pick with 27. 4% revenue growth year-over-year, versus -92. 7% for Nuburu, Inc. (BURU). NPK International Inc. (NPKI) offers the better valuation at 36. 8x trailing P/E (29. 3x forward), making it the more compelling value choice. Analysts rate IPG Photonics Corporation (IPGP) a "Buy" — based on 27 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, NPK International Inc.

(NPKI) is the cheapest at 36. 8x versus IPG Photonics Corporation at 139. 2x. On forward P/E, NPK International Inc. is actually cheaper at 29. 3x.

Over the past 5 years, NPK International Inc.

(NPKI) delivered a total return of +91. 5%, compared to -99. 9% for Nuburu, Inc. (BURU). Over 10 years, the gap is even starker: NPKI returned +91. 5% versus LYRA's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Lyra Therapeutics, Inc.

(LYRA) is the lower-risk stock at 0. 65β versus IPG Photonics Corporation's 1. 80β — meaning IPGP is approximately 179% more volatile than LYRA relative to the S&P 500. On balance sheet safety, NPK International Inc. (NPKI) carries a lower debt/equity ratio of 10% versus 3% for Lyra Therapeutics, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), NPK International Inc.

(NPKI) is pulling ahead at 27. 4% versus -92. 7% for Nuburu, Inc. (BURU). On earnings-per-share growth, the picture is similar: NPK International Inc. grew EPS 124. 0% year-over-year, compared to -13. 5% for Lyra Therapeutics, Inc.. Over a 3-year CAGR, LYRA leads at 75. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

NPK International Inc.

(NPKI) is the more profitable company, earning 13. 0% net margin versus -226. 9% for Nuburu, Inc. — meaning it keeps 13. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: NPKI leads at 16. 9% versus -86. 4% for BURU. At the gross margin level — before operating expenses — LYRA leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, NPK International Inc.

(NPKI) trades at 29. 3x forward P/E versus 62. 6x for IPG Photonics Corporation — 33. 3x cheaper on a one-year earnings basis.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Lyra Therapeutics, Inc.

(LYRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 65)). IPG Photonics Corporation (IPGP) carries a higher beta of 1. 80 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LYRA: -100. 0%, IPGP: +20. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (BURU (Industrials) and IPGP (Technology) and LYRA (Healthcare) and LASE (Industrials) and NPKI (Energy)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: BURU is a small-cap quality compounder stock; IPGP is a small-cap quality compounder stock; LYRA is a small-cap quality compounder stock; LASE is a small-cap quality compounder stock; NPKI is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.